Europe biopharmaceuticals market was valued at $116.5 billion in 2023 and will grow by 8.6% annually over 2023-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical trials and approvals for novel biomedicines, escalating healthcare spending, and favorable reimbursement policies.
Highlighted with 43 tables and 86 figures, this 160-page report "Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service, Raw Material (Excipients, API, Others), Classification (Innovative, Biogenerics and Biosimilars), Therapeutic Area, and Country: Trend Forecast and Growth Opportunity" is based on comprehensive research of the entire Europe biopharmaceuticals market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify the Europe biopharmaceuticals market in every aspect of the classification from perspectives of Product Type, Testing Service, Raw Material, Classification, Therapeutic Area and Country.
Based on Product Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Monoclonal Antibodies
o Anti-cancer Monoclonal Antibodies
o Anti-inflammatory Monoclonal Antibodies
o Other Monoclonal Antibodies
• Recombinant Growth Factors
o Erythropoietin
o Granulocyte Colony Stimulating Factor
• Purified Proteins
o Leukemia Inhibitory Factor (LIF)
o P53 Protein
o P38 Protein
o Other Purified Proteins
• Recombinant Proteins
o Serum Albumin
o Amyloid Protein
o Defensin
o Transferrin
• Recombinant Hormones
o Recombinant Human Growth Hormones
o Recombinant Insulin
o Other Recombinant Hormones
• Vaccines
o Recombinant Vaccines
Cancer Vaccines
Malaria Vaccines
Ebola Vaccines
Hepatitis Vaccines
Tetanus Vaccines
Diphtheria Vaccines
Cholera Vaccines
Other Recombinant Vaccines
o Conventional Vaccines
Polio Vaccines
Pox Vaccines
Other Conventional Vaccines
• Recombinant Enzymes
o Enterokinase
o Cyclase
o Caspase
o Cathepsin
• Cell and Gene Therapies
o Allogenic Products
o Autologous Products
o Acellular Products
• Synthetic Immunomodulators
• Other Product Types
o Blood Factors
o Other Products
Based on Testing Service, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Laboratory Testing
• Custom Testing/Customer Proprietary Testing
• Compendial and Multi Compendial Laboratory Testing
By Raw Material, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Formulation Excipients
• Active Pharmaceutical Ingredients (API)
• Other Materials
By Classification, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Innovative Biopharmaceuticals
• Biogenerics and Biosimilars
By Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2023-2033 included in each section.
• Oncology
• Inflammatory and Infectious Diseases
• Autoimmune Disorders
• Metabolic Disorders
• Hormonal Disorders
• Cardiovascular Diseases
• Neurological Diseases
• Other Therapeutic Areas
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Netherlands
• Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2023-2033. The breakdown of national markets by Product Type and Therapeutic Area over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Laboratories
Amgen Inc.
Astrazeneca PLC
Bayer AG
Biogen Inc.
Bristol-myers Squibb Company (BMS)
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Glaxosmithkline PLC
Johnson & Johnson
Merck & Co. Inc.
Novartis Ag
Novo Nordisk As
Pfizer Inc.
Sanofi Sa
Sharp Packaging Services
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals
WuXi AppTec
(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 26
2.1.3 Impact of Russia-Ukraine Conflict 28
2.1.4 Impact of Israel-Palestine War 30
2.2 Major Growth Drivers 31
2.3 Market Restraints and Challenges 40
2.4 Emerging Opportunities and Market Trends 43
2.5 Porter's Fiver Forces Analysis 47
3 Segmentation of Europe Market by Product Type 51
3.1 Market Overview by Product Type 51
3.2 Monoclonal Antibodies 53
3.2.1 Anti-cancer Monoclonal Antibodies 54
3.2.2 Anti-inflammatory Monoclonal Antibodies 55
3.2.3 Other Monoclonal Antibodies 56
3.3 Recombinant Growth Factors 57
3.3.1 Erythropoietin 58
3.3.2 Granulocyte Colony Stimulating Factor 59
3.4 Purified Proteins 60
3.4.1 Leukemia Inhibitory Factor (LIF) 61
3.4.2 P53 Protein 62
3.4.3 P38 Protein 63
3.4.4 Other Purified Proteins 64
3.5 Recombinant Proteins 65
3.5.1 Serum Albumin 66
3.5.2 Amyloid Protein 67
3.5.3 Defensin 68
3.5.4 Transferrin 69
3.6 Recombinant Hormones 70
3.6.1 Recombinant Human Growth Hormones 71
3.6.2 Recombinant Insulin 73
3.6.3 Other Recombinant Hormones 74
3.7 Vaccines 75
3.7.1 Recombinant Vaccines 76
3.7.2 Conventional Vaccines 78
3.8 Recombinant Enzymes 79
3.8.1 Enterokinase 80
3.8.2 Cyclase 81
3.8.3 Caspase 82
3.8.4 Cathepsin 83
3.9 Cell and Gene Therapies 84
3.9.1 Allogenic Products 85
3.9.2 Autologous Products 86
3.9.3 Acellular Products 87
3.10 Synthetic Immunomodulators 88
3.11 Other Product Types 89
3.11.1 Blood Factors 90
3.11.2 Other Products 91
4 Segmentation of Europe Market by Testing Service 92
4.1 Market Overview by Testing Service 92
4.2 Laboratory Testing 94
4.3 Custom Testing/Customer Proprietary Testing 95
4.4 Compendial and Multi Compendial Laboratory Testing 96
5 Segmentation of Europe Market by Raw Material 97
5.1 Market Overview by Raw Material 97
5.2 Formulation Excipients 99
5.3 Active Pharmaceutical Ingredients (API) 100
5.4 Other Materials 101
6 Segmentation of Europe Market by Classification 102
6.1 Market Overview by Classification 102
6.2 Innovative Biopharmaceuticals 104
6.3 Biogenerics and Biosimilars 105
7 Segmentation of Europe Market by Therapeutic Area 106
7.1 Market Overview by Therapeutic Area 106
7.2 Oncology 108
7.3 Inflammatory and Infectious Diseases 109
7.4 Autoimmune Disorders 110
7.5 Metabolic Disorders 111
7.6 Hormonal Disorders 112
7.7 Cardiovascular Diseases 113
7.8 Neurological Diseases 114
7.9 Other Therapeutic Areas 115
8 European Market 2023-2033 by Country 116
8.1 Overview of European Market 116
8.2 Germany 119
8.3 U.K. 121
8.4 France 123
8.5 Spain 125
8.6 Italy 127
8.7 Netherlands 129
8.8 Rest of European Market 131
9 Competitive Landscape 133
9.1 Overview of Key Vendors 133
9.2 New Product Launch, Partnership, Investment, and M&A 137
9.3 Company Profiles 138
Abbott Laboratories 138
Amgen Inc. 140
Astrazeneca PLC 141
Bayer AG 142
Biogen Inc. 143
Bristol-myers Squibb Company (BMS) 144
Eli Lilly and Company 145
F. Hoffmann-La Roche Ltd. 146
Glaxosmithkline PLC 147
Johnson & Johnson 148
Merck & Co. Inc. 149
Novartis Ag 150
Novo Nordisk As 151
Pfizer Inc. 152
Sanofi Sa 153
Sharp Packaging Services 154
Sun Pharmaceutical Industries Ltd. 155
Takeda Pharmaceutical Company Limited 156
Thermo Fisher Scientific Inc. 157
Vertex Pharmaceuticals 158
WuXi AppTec 159
RELATED REPORTS 160
Industrial protective clothing constitutes specialized attire fabricated from engineered textiles intended to safeguard personnel operating amid potentially perilous occupational environments from exposure to myriad hazards inherent to industrial settings such as manufacturing plants, construction s...
Europe cutting tools market was valued at $6.85 billion in 2023 and will grow by 4.6% annually over 2023-2033. The growth is driven by the increasing production and manufacturing activities, improved operational efficiency and innovative design, and an increasing demand for power tools for DIY activ...
Europe paper machine clothing (PMC) market was valued at $ 631.1 million in 2023 and will grow by 3.6% annually over 2023-2033. The growth is driven by the increasing demand for paper and paper-based products across various industries, technological advancements in the papermaking process, the intro...
Europe endoscopy devices market was valued at $10.1 billion in 2023 and will grow by 5.9% annually over 2023-2033. The growth is driven by the increasing prevalence of chronic diseases, the growing demand for less invasive procedures, a rising adoption of disposable endoscopic components, growing ge...
Europe digital health and wellness market was valued at $100.9 billion in 2023 and will grow by 18.9% annually over 2023-2033. The growth is driven by an increasing number of chronic diseases, the growing investment in health and wellness programs, the increased use of smartphones and wearable devic...
Europe connected healthcare device market was valued at $16 billion in 2023 and will grow by 19.2% annually over 2023-2033. The growth is driven by the emergence of telehealth and telemedicine services, benefits such as reliability and effective patient monitoring, the penetration of mobile and inte...
Europe bioprocess technology market was valued at $6.56 billion in 2023 and will grow by 13.7% annually over 2023-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing tech...
Asia Pacific biopharmaceuticals market will grow by 10.3% annually with a total addressable market cap of $1,776.7 billion over 2024-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discove...
Europe biopharmaceuticals market was valued at $116.5 billion in 2023 and will grow by 8.6% annually over 2023-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical t...
North America biopharmaceuticals market is projected to grow by 8.4% annually in the forecast period and reach $407.2 billion by 2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, ...